Highlights of This Issue 4917

SPECIAL FEATURES

CCR Translations

4919

Why Is This Effective HSP90 Inhibitor Not Being Developed in HER2+ Breast Cancer?
Carlos L. Arteaga
See article p. 5132

CCR New Strategies

4922

New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances
Keith T. Flaherty and David E. Fisher

Editor's Note

4929

Introducing CCR Perspectives in Drug Approval
James L. Abbruzzese

CCR Perspectives in Drug Approval

4930

The National Institute for Health and Clinical Excellence and Its Role in Assessing the Value of New Cancer Treatments in England and Wales
Rebecca Trowman, Helen Chung, Carole Longson, Peter Littlejohns, and Peter Clark

Molecular Pathways

4936

Stem Cell Quiescence
Ling Li and Ravi Bhataia

4942

Cancer Stem Cells and Chemosensitivity
Marcello Maugeri-Saccà, Paolo Vigneri, and Ruggero De Maria

Review

4948

Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation
Per E. Lønning, Ben P. Haynes, Anne H. Straume, Anita Dunibier, Hildegunn Helle, Stian Knappskog, and Mitch Dowsett

Perspective

4959

To DNA or not to DNA? That is the Question, When It Comes to Molecular Subtyping for the Clinic!
Serge J. Smeets, Ulrike Harjes, Wessel N. van Wieringen, Daoudiee, Ruud H. Brakenhoff, Gerrit A. Meijer, and Bauke Ylstra

HUMAN CANCER BIOLOGY

4965

Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma

4975

Interleukin-7 Inhibits Tumor-Induced CD27−CD28− Suppressor T Cells: Implications for Cancer Immunotherapy
Yue Zhang, Lukas W. Pfannenstiel, Elzbieta Boleda, Carolina L. Montes, Xiaoju Zhang, Andrei I. Chapoval, Ronald B. Gartenhaus, Scott E. Stromme, and Brian R. Gastman

CANCER THERAPY: PRECLINICAL

4987

Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression
Qiao Li, Xiangming Lan, Qin Pan, Ning Ning, Ji Yet, Yingxin Xu, Shengping Li, and Alfred E. Chang
Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab
Neil E. Bhola, Sufi M. Thomas, Maria Freilino, Sonali Joyce, Anirban Sahu, Jessica Maxwell, Athanasios Arigiris, Raja Seethala, and Jennifer R. Grandis

Enhanced Metastasis Suppression by Targeting TRAIL Receptor 2 in a Murine Model of Triple-Negative Breast Cancer
Dmitry Malin, Feng Chen, Carol Schiller, Jennifer Koblinski, and Vincent L. Cryns

Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells
Marianne E. Marshall, Trista K. Hinz, Scott A. Kono, Katherine R. Singleton, Brady Bichon, Kathryn E. Ware, Lindsay Marek, Barbara A. Frederic, David Raben, and Lynn E. Heasley

Mitoxantrone Inhibits HIF-1α Expression in a Topoisomerase II–Independent Pathway
Ying-Min Toh and Tsai-Kun Li

Enhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK Inhibition
Mary Ellen Urick, Eun Joo Chung, William P. Shield, III, Naamit Gerber, Ayla White, Anastasia Sowers, Angela Thetford, Kevin Camphausen, James Mitchell, and Deborah E. Citrin

The Efficacy of IGF-1 Receptor Monoclonal Antibody against Human Gastrointestinal Carcinomas is Independent of k-ras Mutation Status
Hiroyuki Yamamoto, Hirokazu Ohashi, Hiroaki Taniguchi, Yoshiaki Arimura, David P. Carbone, Koohzeh Imai, and Yatsuisha Shinomura

Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
Yoriko Yamashita-Kashima, Shigeki Sera, Keigo Yorozu, Koh Furugaki, Mitsue Kurasawa, Masanori II, Hua Li, Yasushi Adachi, Hirokazu Ohashi, and Ryoichi Shinomura

HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors
Rafał Zielinski, Ilya Lyakhov, Moinuddin Hassan, Monika Kubañ, Kimberly Shafer-Weaver, Amir Gandjbakhche, and Jacek Capala

High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Johannes H. Schulte, Hagen S. Bachmann, Bent Brockmeyer, Kathleen DePreter, André Obertshür, Sandra Ackermann, Yvonne Kahler, Kristian Pagtiler, Jessica Theissen, Frank Westermann, Jo Vandesompele, Frank Speelman, Frank Berthold, Angelika Eggert, Benedikt Brors, Barbara Hero, Alexander Schramm, and Matthias Fischer

FDG-PET as a Potential Tool for Selecting Patients with Advanced Non–Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy
Dok Hyun Yoon, Sora Baek, Chang-Min Moon, Dae Hyuk Moon, Jung Shin Lee, and Sang-We Kim

Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma
Marc A. Weniger, Edgar G. Bizzatti, Patricia Perez-Galan, Delong Liu, Qiuyan Wang, Peter J. Munson, Nalini Raghavachari, Therese White, Megan M. Tweito, Kieron Dunleavy, Yihong Ye, Wyndham H. Wilson, and Adrian Wiestner

Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children’s Oncology Group Study
Steven G. DuBois, Suzanne Shusterman, Ashish M. Ingle, Charlotte H. Ahern, Joel M. Reid, Bing Wu, Sylvain Baruchel, Julia Glade-Bender, Percy Ivy, Holcombe E. Grier, Peter C. Adamson, and Susan M. Blaney

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors
Shivani Kummer, Mark Raffeld, Lamin Juwara, Yvonne Hornfeffer, Agnes Strassberger, Deborah Allen, Seth M. Steinberg, Annamaria Rapisarda, Shawn D. Spencer, William D. Figg, Xiaohong Chen, Ismail Baris Turkbey, Peter Choyke, Anthony J. Murgo, James H. Doroshow, and Giovanni Melillo
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Shanu Modi, Alison Stopeck, Hannah Linden, David Solit, Sarat Chandarlapaty, Ne...
ABOUT THE COVER

Three-dimensional structure of the trastuzumab/pertuzumab/HER2 ternary complex. Yellow, orange, and magenta are trastuzumab, pertuzumab, and HER2, respectively. Trastuzumab and pertuzumab bind to HER2 without competing with each other. For further details, please see Yamashita-Kashima and coworkers on page 5060 in this issue.
Clinical Cancer Research

17 (15)

*Clin Cancer Res* 2011;17:4917-5214.

| Updated version | Access the most recent version of this article at: [http://clincancerres.aacrjournals.org/content/17/15](http://clincancerres.aacrjournals.org/content/17/15) |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |